Major pharmaceutical firm Pfizer Inc. said its COVID-19 antiviral candidate PAXLOVID has significantly reduced hospitalization and death, the company announced in a statement.
- Pfizer said interim analysis showed an 89% reduction in risk of COVID-19 related hospitalization or death from any case for patients treated within three days of symptom onset.
- The data indicated that there were lower hospitalizations for those who took the pill, and the statistical significance of the results was high. Significant reductions were also observed in patients treated within five days of onset.
- Upon recommendation, Pfizer said it will stop further enrollment into the study due to the “overwhelming efficacy” showed by the results, and the data will be submitted to the US Food and Drug Administration (FDA) as soon as possible.
Should it be approved, PAXLOVID will be the first oral antiviral of its kind. PFE is up 7.86%.